@article{3102336,
    title = "Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B",
    author = "Papatheodoridis, G.V. and Dalekos, G.N. and Idilman, R. and Sypsa, V. and Van Boemmel, F. and Buti, M. and Calleja, J.L. and Goulis, J. and Manolakopoulos, S. and Loglio, A. and Papatheodoridi, M. and Gatselis, N. and Veelken, R. and Lopez-Gomez, M. and Hansen, B.E. and Savvidou, S. and Kourikou, A. and Vlachogiannakos, J. and Galanis, K. and Yurdaydin, C. and Esteban, R. and Janssen, H.L.A. and Berg, T. and Lampertico, P.",
    journal = "JHEP Reports",
    year = "2021",
    volume = "3",
    number = "3",
    publisher = "Elsevier B.V.",
    doi = "10.1016/j.jhepr.2021.100290",
    keywords = "albumin;  entecavir;  tenofovir disoproxil, adult;  age;  age albumin sex liver cirrhosis score;  Article;  Asian hepatocellular carcinoma risk score;  cancer incidence;  cancer risk;  carcinogenesis;  Caucasian;  chronic hepatitis B;  cirrhosis age male gender diabetes score;  clinical practice;  cohort analysis;  compensated liver cirrhosis;  female;  follow up;  gender;  hepatocellular carcinoma risk estimating score in chronic hepatitis B under entecavir.;  high risk patient;  human;  liver cell carcinoma;  low risk patient;  major clinical study;  male;  middle aged;  modified platelets age gnder score;  predictive value;  predictor variable;  scoring system;  sensitivity and specificity;  thrombocyte;  treatment duration",
    abstract = "Background & Aims: Recently, several risk scores for prediction of hepatocellular carcinoma (HCC) were developed in cohorts of treated Asian patients with chronic hepatitis B (CHB), but they have not been assessed in non-Asian patients. We evaluated the predictability and comparative utility of our PAGE-B and recent Asian HCC risk scores in nucleos(t)ide analogue (NA)-treated adult Caucasian patients with CHB, with or without well-documented compensated cirrhosis but not previous diagnosis of HCC. Methods: We included 1,951 patients treated with entecavir/tenofovir and followed up for a median of 7.6 years. The c-statistic was used to estimate the predictability of PAGE-B, HCC-Rescue, CAMD, mPAGE-B, and AASL score for HCC development within 5 or 10 years. The low- and high-risk group cut-offs were used for estimation of negative (NPV) and positive predictive values (PPV), respectively. Results: HCC developed in 103/1,951 (5.3%) patients during the first 5 years and in another 39/1,428 (2.7%) patients between years 5 and 10. The 3-, 5-, and 10-year cumulative HCC rates were 3.3%, 5.9%, and 9.6%, respectively. All scores offered good 5- and 10-year HCC prediction (c-statistic: 0.78–0.82). NPVs were always >99% (99.3–100%), whereas PPV ranged between 13% and 24%. Conclusions: In NA-treated Caucasian patients with CHB including compensated cirrhosis, HCC risk scores developed in NA-treated Asian patients offer good 5- and 10-year HCC predictability, similar to that of PAGE-B. PAGE-B and mPAGE-B scores are simpler in clinical practice, as they do not require an accurate diagnosis of cirrhosis, but the addition of albumin in mPAGE-B score does not seem to offer an advantage in patients with well compensated liver disease. Lay summary: Several risk scores for prediction of hepatocellular carcinoma (HCC) were recently developed in cohorts of treated Asian patients with chronic hepatitis B (CHB). In Caucasian patients with CHB treated with oral antivirals, newer Asian HCC risk scores offer good 5- and 10-year HCC predictability, similar to that of PAGE-B. For clinical practice, PAGE-B and mPAGE-B scores are simpler, as they do not require an accurate diagnosis of cirrhosis. © 2021 The Authors"
}